Apolipoprotein E gene alleles have been linked to various cardiovascular and neurodegenerative disorders. There have been conflicting reports of associations between Apolipoprotein E alleles and Parkinson disease and Parkinson disease dementia. To investigate the role of Apolipoprotein E alleles in Parkinson disease and Parkinson disease dementia, we have determined Apolipoprotein E genotypes in a group of patients with Parkinson disease (n = 95) and compared them with those of healthy control participants (n = 73). Additionally, in 64 longitudinally followed patients with Parkinson disease, the allele types were correlated to development and progression of dementia and to time from onset of Parkinson disease to dementia using multivariate and survival analyses. The Apolipoprotein E e4e4 genotype was more common in patients with Parkinson disease (7.4%) than in healthy controls (1.4%; P = .03). No significant associations between the Apolipoprotein E genotype and development and progression of dementia or time to dementia were found. More studies with larger Parkinson disease samples are warranted.
Hughes AJ, Daniel SE, Blankson S., Lees AJA clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol. 1993;50:140-148.
2.
Marder K., Tang MX, Alfaro B., et al. Risk of Alzheimer’s disease in relatives of Parkinson’s disease patients with and without dementia. Neurology. 1999;52:719-724.
3.
Kurz M., Alves G., Aarsland D., Larsen JPFamilial Parkinson’s disease: a community-based study. Eur J Neurol. 2003;10:159-163.
4.
Gasser T.Update on the genetics of Parkinson’s disease. Mov Disord . 2007;22(suppl 17):S343-S350.
5.
Serretti A., Olgiati P., De Ronchi D.Genetics of Alzheimer’s disease.A rapidly evolving field. J Alzheimers Dis. 2007;12:73-92.
6.
Kuehn BMScientists probe role of genes, environment in Parkinson disease. JAMA. 2006;295:1883-1885.
7.
Aarsland D., Zaccai J., Brayne C.A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20:1255-1263.
8.
Aarsland D., Andersen K., Larsen JP, Lolk A., KraghSørensen P.Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387-392.
9.
Buter TC, Van Den Hout A., Matthews FE, Larsen JP, Brayne C., Aarsland D.Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70:1017-1022.
10.
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JGThe Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837-844.
11.
Aarsland D. , Larsen JP, Tandberg E., Laake K.Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48:938-942.
12.
Levy G., Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD. Neurology. 2002;59:1708-1713.
13.
Kurz MW, Schlitter AM, Larsen JP, Ballard C., Aarsland D.Familial occurrence of dementia and parkinsonism: a systematic review. Dement Geriatr Cogn Disord. 2006;22:288-295.
14.
Mahley RW, Rall SC Jr.Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-537.
15.
Levy-Lahad E. , Tsuang D., Bird TDRecent advances in the genetics of Alzheimer’s disease. J Geriatr Psychiatry Neurol. 1998 ;11:42-54.
16.
Jellinger KAMorphological substrates of parkinsonism with and without dementia: a retrospective clinicopathological study. J Neural Transm Suppl. 2007;91-104.
17.
Tsuang DW, Wilson RK, Lopez OL, et al. Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease. Neurology. 2005;64:509-513.
18.
Wakabayashi K. , Kakita A., Hayashi S., et al. Apolipoprotein E epsilon4 allele and progression of cortical Lewy body pathology in Parkinson’s disease. Acta Neuropathol (Berl). 1998;95:450-454.
19.
Ghebremedhin E., Del Tredici K., Vuksic M., et al. Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology. J Neuropathol Exp Neurol. 2006;65:116-123.
20.
Huang X., Chen P., Kaufer DI, Tröster AI, Poole C.Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol. 2006;63:189-193.
21.
Jasinska-Myga B., Opala G., Goetz CG, et al. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol. 2007;64:261-265.
22.
Tandberg E. , Larsen JP, Nessler EG, et al. The epidemiology of Parkinson’s disease in the county of Rogaland, Norway. Mov Disord. 1995;10:541-549.
23.
Larsen JP, Dupont E., Tandberg E.Clinical diagnosis of Parkinson’s disease.Proposal of diagnostic subgroups classified at different levels of confidence . Acta Neurol Scand. 1994;89:242-251.
24.
Aarsland D. , Perry R., Brown A., Larsen JP, Ballard C.Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study. Ann Neurol . 2005;58:773-776.
25.
Fahn S., Elton RL, Committee Motud. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Liebermann A, eds. Recent Development in Parkinson’s Disease . Florham Park, NJ: Macmillan Health Care Information; 1987:153-163.
26.
Folstein MF , Folstein SE, Mchugh PR‘‘Mini-Mental State’’: A practical method for grading the mental state of patients for the clinician . J Psychiatr Res. 1975;12:189.
27.
Saft C., Andrich JE, Brune N., et al. Apolipoprotein E genotypes do not influence the age of onset in Huntington’s disease. J Neurol Neurosurg Psychiatry . 2004;75: 1692-1696.
28.
Caballol N. , Marti MJ, Tolosa E.Cognitive dysfunction and dementia in Parkinson disease. Mov Disord. 2007;22:S358-S366.
29.
Blazquez L. , Otaegui D., Saenz A., et al. Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson’s disease. Neurosci Lett. 2006;406:235-239.
30.
Lopez M., Guerrero J., Yescas P., et al. Apolipoprotein E epsilon4 allele is associated with Parkinson disease risk in a Mexican Mestizo population. Mov Disord. 2007;22: 417-420.
31.
Li YJ, Hauser MA, Scott WK, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004;62:2005-2009.
32.
Pankratz N. , Byder L., Halter C., et al. Presence of an APOE4 allele results in significantly earlier onset of Parkinson’s disease and a higher risk with dementia. Mov Disord. 2006;21:45-49.
33.
Zareparsi S. , Kaye J., Camicioli R., et al. Modulation of the age at onset of Parkinson’s disease by apolipoprotein E genotypes. Ann Neurol. 1997;42:655-658.
34.
Parsian A., Racette B., Goldsmith LJ, Perlmutter JSParkinson’s disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics. 2002 ;79:458-461.
35.
Apolipoprotein E genotype in familial Parkinson’s disease.The French Parkinson’s Disease Genetics Study Group. J Neurol Neurosurg Psychiatry. 1997 ;63: 394-395.
36.
Harhangi BS , De Rijk MC, Van Duijn CM, et al. APOE and the risk of PD with or without dementia in a population-based study. Neurology. 2000;54:1272-1276.
37.
Huang X., Chen PC, Poole C.APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology. 2004;62:2198-2202.
38.
de Lau LM, Schipper CM, Hofman A., Koudstaal PJ, Breteler MMPrognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol. 2005;62:1265-1269.
